Trial Profile
Phase 2 study of KRN125 (A dose finding study of KRN125 for chemotherapy-induced neutropenia in breast cancer)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Feb 2020
Price :
$35
*
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Neutropenia
- Focus Therapeutic Use
- Sponsors Kyowa Hakko Kirin; Kyowa Kirin
- 27 May 2016 New trial record